The prevalence of type 2 diabetes has increased as a result of rising obesity rates and the aging population. Antidiabetic drug Pioglitazone alone or in combination with metformin, repaglinide, insulin, or sulphonylurea led to both long-term and short-term improvements in glycaemic control and serum lipid profiles. Additionally, several studies have shown that Pioglitazone does not raise cardiovascular risk and might exhibit some cardiovascular protective effects.
Professor of Endocrinology in the Department of Endocrinology at Osmania Medical College
MBBS, DNB, MD (Internal medicine), DM (Endocrinology), FACE, FICP. Diabetologist and Endocrinologist based in Hyderabad. Currently is available for consultation at Medicity Hospital and the Sahay Endocrine and Diabetes Centre, by appointment. Professor of Endocrinology in the Department of Endocrinology at Osmania Medical College. Have been the Principal Investigator for several multi-centric multi-national clinical trials of drugs for diabetes, hypertension and hyperlipidemia and osteoporosis (ICHï¿½GCP compliant). Has a keen interest in writing professionally with about 50 publications in peer-reviewed journals and several contributed chapters in textbooks. Has been invited as a speaker at various national conferences organised by professional bodies such as RSSDI, APICON and the Indian Thyroid Society. Associated with several national and international professional bodies as an office-bearer or life member and has played an active role in organizing some of their events.
Priyanka Joshi is a Doctor of Medicine and medical Advisor of USV
Dr. Priyanka Joshi is a Doctor of Medicine and medical Advisor of USV.